Michael Friedman - Smith Nephew Non-Executive Independent Director
| SNNUF Stock | USD 12.39 0.31 2.57% |
Director
Dr. Michael A. Friedman, M.D., was NonExecutive Independent Director of Smith Nephew PLC. Michael graduated with a Bachelor of Arts degree, magna cum laude from Tulane University and a Doctorate in Medicine from the University of Texas Southwestern Medical Center. He completed postdoctoral training at Stanford University and the National Cancer Institute, and is board certified in Internal Medicine and Medical Oncology. In 1983, he joined the Division of Cancer Treatment at the National Cancer Institute and went on to become the Associate Director of the Cancer Therapy Evaluation Program. Michael was most recently CEO of City of Hope in California, and also served as Director of the institutions cancer centre and held the Irell Manella Cancer Center Directors Distinguished Chair. He was formerly Senior VP of research, medical and public policy for Pharmacia Corporation and also Deputy Commissioner and Acting Commissioner at the US Food and Drug Administration . He has served on a number of boards in a nonexecutive capacity, including Rite Aid Corporationrationration. Currently, Michael is a NED of Celgene Corporationrationration, MannKind Corporation and Intuitive Surgical, Inc. Michael understands the fundamental importance of research, which is part of Smith Nephews value creation process. His varied experience in both the public and private healthcare sectors have given him a deep insight and a highly respected career. In particular his work with the FDA and knowledge relating to US compliance provides the skillset required to Chair the Ethics Compliance Committee. since 2013.
| Age | 73 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Phone | 44 1923 477 100 |
| Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Andrea Goldsmith | Medtronic PLC | 56 | |
| Amy Wendell | Axogen Inc | 57 | |
| Richard Anderson | Medtronic PLC | 65 | |
| Peter Robinson | Paragon 28 | 64 | |
| Samuel Riccitelli | Orthopediatrics Corp | 59 | |
| Lisa Colleran | Axogen Inc | 59 | |
| Jerome Lande | CONMED | 45 | |
| Alan Levine | Axogen Inc | 50 | |
| Austin Adams | Paragon 28 | 71 | |
| David Bronson | CONMED | 67 | |
| Filippo Passerini | Integer Holdings Corp | 63 | |
| Mike Donovan | Axogen Inc | 53 | |
| Olav Bergheim | Glaukos Corp | 64 | |
| David Hoffmeister | Glaukos Corp | 66 | |
| Andrea Saia | LivaNova PLC | 60 | |
| Alan Kozlowski | Orthopediatrics Corp | 51 | |
| Joseph Mandato | Axogen Inc | 70 | |
| Pamela Bailey | Integer Holdings Corp | 72 | |
| Nathaniel Woodson | Paragon 28 | 72 | |
| Robert Rudelius | Axogen Inc | 62 | |
| James Lenehan | Medtronic PLC | 71 | |
Management Performance
| Return On Equity | 0.0925 | |||
| Return On Asset | 0.0425 |
Smith Nephew plc Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Namal Nawana, CEO, Executive Director | ||
| Michael Friedman, Non-Executive Independent Director | ||
| Diogo MoreiraRato, President - Europe and Canada | ||
| Alison Parkes, Chief Officer | ||
| Skip Kiil, President - Orthopedics | ||
| Erik Engstrom, Non-Executive Director | ||
| Deepak Nath, CEO Director | ||
| Matthew Stober, President - Global Operations | ||
| Marc Owen, Non-Executive Director | ||
| AnneFrancoise Nesmes, CFO Director | ||
| Helen Barraclough, Company Counsel | ||
| Rodrigo Bianchi, President IRAMEA | ||
| Brian Larcombe, Senior Independent Non-Executive Director | ||
| Elga Lohler, Chief Human Resource Officer | ||
| Bradley Cannon, Sports Orthopaedics | ||
| Gunthorp Oie, IR Contact Officer | ||
| Roland Diggelmann, Non-Executive Director | ||
| Helen Maye, Chief Human Resources Officer | ||
| Vinita Bali, Non-Executive Director | ||
| Simon Fraser, President - Advanced Wound Management | ||
| Massimiliano Colella, President Europe - Middle East and Africa | ||
| Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
| Graham Baker, CFO, Executive Director | ||
| Cathy ORourke, Chief Legal and Compliance Officer | ||
| Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
| Joe Metzger, VP Communications | ||
| Cyrille Petit, Chief Corporate Development Officer | ||
| Julie Brown, CFO, Director and Member of Disclosures Committee | ||
| Glenn Warner, President - Advanced Wound Management | ||
| Robin Freestone, Non-Executive Director | ||
| Paul Connolly, Pres Operations | ||
| Virginia Bottomley, Non-Executive Independent Director | ||
| Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
| Angie Risley, Non-Executive Director | ||
| Mark Gladwell, President - Global Operations | ||
| Andrew Swift, VP Relations | ||
| Vasant Padmanabhan, President - Research & Development | ||
| Michael Frazzette, President - Advanced Surgical Devices | ||
| Joseph Papa, Non-Executive Independent Director | ||
| Ingeborg Oie, VP, Investor Relations | ||
| Susan Swabey, Company Secretary | ||
| Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
| Philip Cowdy, Chief Officer | ||
| Gordon Howe, President of Global Operations | ||
| John Campo, Chief Legal Officer | ||
| Brad Cannon, President Europe and Canada | ||
| Ian Barlow, Non-Executive Independent Director | ||
| Catheryn ORourke, Chief Legal Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0925 | |||
| Return On Asset | 0.0425 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 14.08 B | |||
| Shares Outstanding | 873.35 M | |||
| Shares Owned By Insiders | 0.17 % | |||
| Shares Owned By Institutions | 52.60 % | |||
| Price To Earning | 23.41 X | |||
| Price To Book | 2.12 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Smith Nephew in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Smith Nephew's short interest history, or implied volatility extrapolated from Smith Nephew options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Smith Pink Sheet analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |